Status:
COMPLETED
Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)
Lead Sponsor:
Novartis
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered by the Aerolizer de...
Eligibility Criteria
Inclusion
- History of asthma attacks
- Forced expiratory volume in 1 second (measure of how well the lungs are working) is greater than 60% of the predicted value
Exclusion
- Asthma is not stable: patients were admitted to hospital or received emergency room treatment
- Patients whose asthma drugs need changing within the month prior to the start of the study
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00443482
Start Date
February 1 2007
End Date
May 1 2007
Last Update
March 28 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Berlin, Germany
2
Novartis Investigative Site
Bovenden--Lengler, Germany
3
Novartis Investigative Site
Marburg, Germany
4
Novartis Investigative Site
Wiesbaden, Germany